Linked Life Data

17993235

Source:http://linkedlifedata.com/resource/pubmed/id/17993235

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-11-12
pubmed:abstractText
Despite improvements in breast cancer therapy in recent years, additional therapies need to be developed. New therapies may have activity by themselves or may have utility in combination with other agents. Population, preclinical, and basic data suggest the insulin-like growth factor (IGF) system functions to maintain the malignant phenotype in breast cancer. Since the IGFs act via transmembrane tyrosine kinase receptors, targeting of the key receptors could provide a new pathway in breast cancer. In addition, IGF action enhances cell survival, so combination of anti-IGF therapy with conventional cytotoxic drugs could lead to synergistic effects. In this review, we will discuss the rationale for targeting the IGF system, potential methods to disrupt IGF signaling, and identify potential interactions between IGF inhibitors and other anti-tumor strategies. We will also identify important issues to consider when designing clinical trials.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0065-2598
pubmed:author
pubmed:issnType
Print
pubmed:volume
608
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
101-12
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Insulin-like growth factors and breast cancer therapy.
pubmed:affiliation
Department of Pharmacology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA.
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural